Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors
Status:
Completed
Trial end date:
2016-08-09
Target enrollment:
Participant gender:
Summary
This is a pilot study of sorafenib in patients with BRAF Mutation Refractory Solid Tumors.
This study is a single-arm, pilot study of sorafenib in patients with Refractory Solid Tumors
harboring BRAF Mutation Sorafenib 400 mg will be administered orally twice a day for 28 days.
To investigate the efficacy of sorafenib in patients with Refractory Solid Tumors harboring
BRAF Mutation.